KADCYLA is the first HER2-targeted treatment of its kind for previously treated metastatic breast cancer

KADCYLA  is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.

How KADCYLA is thought to work

KADCYLA treatment targets HER2

  • KADCYLA is a targeted treatment
  • When you take KADCYLA, you are getting both HER2-targeted treatment and chemotherapy—at the same time

KADCYLA fights cancer from the inside

  • KADCYLA is made to bring chemotherapy inside HER2-positive (HER2+) cells and kill them
  • KADCYLA can cause serious side effects, and may still impact normal cells

What to know about KADCYLA

See the possible benefits and risks of KADCYLA treatment.

Getting started with KADCYLA

What to expect when you receive KADCYLA.